🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Just heard that our NIH funding to learn how to make broadly effective vaccines against pandemic threat coronaviruses is being terminated Lysenko is in charge at NIH

Please apply if you are an early career cancer researcher. Outstanding program and opportunity The Mark Foundation for Cancer Research: themarkfoundation.org/emerging-leade…

Must read.

Balancing the scientific advancement of prevention and treatment is very difficult when your background is in medical oncology. .

👉👉👉Proud to share our brand new collaborative major paper🚨 just out in @BloodJournal led by Prof Marina Konopleva .Marina Konopleva | Efficacy of a Novel #BCLxL Degrader, DT2216 in Preclinical Models of JAK2-m-Post-MPN AML ashpublications.org/blood/article/… | #MPNSM #leusm .Adam Mead

Effective and safe treatment for this disease! #bispecificrocks BU Amyloidosis Center Teclistamab therapy for refractory type 1 cryoglobulinemia pubmed.ncbi.nlm.nih.gov/40109179/

Back in the day, we would call that vaccines and immunizations

The only viable option to prevent the corruption of science by AI is to return to our roots and conduct all business at weekly in-person meetings of the Royal Society in London.

That's simply not true. NCMI, a DIA component, assessed very early, late 2019, that COVID-19 was likely caused by a lab leak (WIV, presumably). That message failed to get traction in the IC because DIA is a 2d-rate agency (and NCMI is small and obscure). That failure was at the

A wholesome thread 🧵 Don't open if you can't handle too much happiness ❣️ 1. Good one

In 1978, Elizabeth Blackburn, a postdoc at Yale University published the structure of telomere (& later discovered telomerase & awarded Nobel prize). 45 years later, we Yale Cancer Center co-led the clinical trial that led to approval of first in class telomerase inhibitor (imetelstat) in #MDSsm

First MMR, now mutated-PIK3CA colorectal. Of course, decreased myeloma seen in ASA takers too. The epidemiologists have done all they can. Time to invest in #CancerPrevention clinical trials. #CancerResearch

To me, these are impressive results and necessary to move forward. But I'm curious if the "I don't like biomarkers" people in the #CancerResearch community are impressed?

For the doctors out there: It’s time we talk about how unfair the business of medicine has become for providers. If you’ve tried to negotiate fair pay with insurance—whether it worked or not—I want to hear your story. Tag me or share it in the comments. We can’t fix what we don’t

📢New hope for AML patients: A study co-authored by The James Alice Mims & Dr. Uma Borate: Associate Professor shows azacitidine+venetoclax+revumenib achieved an 88% response rate in newly diagnosed NPM1-mutated or KMT2A-rearranged AML Journal of Clinical Oncology. Incredible work!🧬🩸 🔗 pubmed.ncbi.nlm.nih.gov/40504618

ROTC programs at Univ. of Northern Iowa, Univ. of Dubuque to shut down kcrg.com/video/2025/07/…

Bye, Linda Yaccarino , sorry we didn't get a chance to talk.

Considering potential reviewers for a submission outside my field (I know, I know), I naively thought that while my field may have all kinds of personal dynamics, surely not in that other field... Surprise! Dynamics are everywhere!